CYP 2C9 Activity Assay, Catalog: MA-0237

Catalog MA-0237

Size 200 reactions

Sample Type Human liver microsomes and liver S9 fractions, Lysates of tissues and cultured cells, primary hepatocytes, Heterologously expressed recombinant CYP2C9 preparations

Method of Detection Fluorometric, Ex/Em = 415 nm/502 nm

Assay Type Quantitative

Application A simple, sensitive means of measuring CYP2C9 activity in a variety of biological samples  

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 family, accounting for ~18% of P450 activity in the liver. It is also present in the duodenum and small intestine where it contributes to first-pass metabolism of orally administered drugs. It has a fairly wide substrate spectrum, metabolizing ~15-20% of drugs that undergo phase I metabolism. Some of the clinically most important substrates include warfarin, particularly the S-isomer, sulfonylureas such as tolbutamide, phenytoin, NSAIDs, particularly diclofenac and ibuprofen, antihypertensives such as Losartan and irbesartan. It is also one of the P450 isoforms responsible for epoxygenase activity, converting arachidonic acid and other polyunsaturated fatty acids to EET’s, biologically active eicosanoids. AkrivisBio’s CYP2C9 is a simple, sensitive assay useful for a variety of biological samples. The use of Sulfaphenazole as a highly specific 2C9 inhibitor allows for a differential assay isolating 2C9 activity from other P450 activities. The reaction is followed at Ex/Emm of 415 nm/502 nm.